None listed
Conditions
Brief summary
The primary aim of the study is to investigate the impact of telmisartan treatment on brown fat in humans. The hypothesis is that telmisartan recruits brown fat in humans, thereby improving glucose metabolism.
Interventions
Arm 1: change from usual blood pressure medication to telmisartan 40-80 mg daily (therapeutic dosage) orally for 4 weeks. Adherence will be monitored by drug tablet return.
Sponsors
Garvan Institute of Medical Research
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
1. BMI: 20-30 kg/m2 2. Disease status: uncomplicated hypertension on mono-therapy (ACE inhibitor or calcium channel blockers (CCB)) with stable blood pressure control for > 6 months. 3. Willingness to give written informed consent and willingness to participate to and comply with the study
Exclusion criteria
* BMI <20 or >30 Kg/m2. * Age <18 or >45 years old. * Pregnant or breast-feeding. * History/laboratory (screening test) evidence of significant cardiovascular, endocrine, neoplastic, renal, hepatic or metabolic disorders, including hyperkalaeamia. * On more than 1 anti-hypertensive medication. * Known hypersensitivity to any angiotensin receptor blocker. * Current diabetes medication therapy (however, patients with pre-diabetes or diet-controlled diabetes not on medication may participate) * On therapies with possible effects on brown fat and or glycemia (e.g. beta-agonists (including inhaled formulations), beta-blockers, alpha-blockers, diuretics, glucocorticoids and/or hormone replacement). * Unwillingness to undergo blood pressure monitoring during treatment phase. * Claustrophobia. * History of illicit drug or alcohol abuse within the last 5 years; current use of drugs (by history) or alcohol (CAGE score>3). * Inability to provide written informed consent * Current use of medications/dietary supplements/alternative therapies known to alter endocrine/metabolic function. * Current use of antiplatelet or anticoagulants (if subjects decide to participate in optional tissue biopsies). * Current smoker or user of tobacco products * Current participation in weight loss programs (dietary, exercise or pharmacological) or more than 3 kg weight changes in last 6 months
Outcome results
None listed